PFPlinio M. Ferreira

Plinio M. Ferreira

*This is an algorithmically generated author record based on publicly available information.

Plinio M. Ferreira has a total of 52 co-authors. Here are the top co-authors by number of shared publications:

  • Paul Charles Armstrong

    Blizard Institute, The Faculty of Medicine and Dentistry, Queen Mary University of London

    3 shared publications
  • Arthur T. Tucker

    A William Harvey Research Institute, Barts & the London School of Medicine & Dentistry , Queen Mary University of London , London , United Kingdom

    2 shared publications
  • Marilena Crescente

    Institute for Cardiovascular and Metabolic Research, School of Biological Sciences, University of Reading, Reading, UK

    2 shared publications
  • Melissa A. Hayman

    A William Harvey Research Institute, Barts & the London School of Medicine & Dentistry , Queen Mary University of London , London , United Kingdom

    2 shared publications
  • Rebecca B. Knowles

    A William Harvey Research Institute, Barts & the London School of Medicine & Dentistry , Queen Mary University of London , London , United Kingdom

    2 shared publications
  • Timothy D. Warner

    A William Harvey Research Institute, Barts & the London School of Medicine & Dentistry , Queen Mary University of London , London , United Kingdom

    2 shared publications

Latest Publications

  • A lexicon for psychedelic research and treatment

    by David J. Nutt, David Erritzoe, Anne Schlag, David Luke, Deborah C. Mash, Hiroyuki Uchida, Jacob S. Aday, James Rucker, Liliana Galindo, Mark Sweeney, et al.

    Psychedelics are undergoing a clinical research renaissance, with compounds such as psilocybin advancing to Phase 3 trials for treatment-resistant depression and receiving fast-track or breakthrough designations from regulatory agencies. Despite this progress, the field lacks standardized terminology to guide clinical development, dosing, safety monitoring, and regulatory classification. Here, we present a comprehensive framework for psychedelic nomenclature based on pharmacology, subjective effects, dosing, and therapeutic use. A pharmacological classification system is described, encompassing serotonergic, glutamatergic, kappaergic, GABAergic, and atypical psychedelics. Dose-dependent categories—microdose, minidose, mididose, and macrodose—are introduced to standardize the description of dosing levels and intended subjective effects. We also standardize vague terms like “short-acting” or “long-acting” with specific pharmacokinetic parameters, including route, onset, and duration of action. Safety considerations are also explored, particularly cardiovascular and psychological effects, and we discuss the need for risk mitigation protocols in higher-risk compounds like ibogaine. The evolving role of psychotherapy in psychedelic treatment is also examined, proposing terminology to distinguish between “psychedelic therapy” and varying levels of psychological support. A three-phase treatment model—preparation, dosing, and integration—is recommended as a minimum standard for safe and effective care. The lack of comparative research on psychotherapy modalities in psychedelic therapy is identified as a critical gap. Ultimately, a standardized lexicon and clinical framework will support clearer communication, improved trial design, and more equitable access as psychedelic therapies move toward widespread clinical use.


  • Open Access

    Platelet mitochondrial transfer via extracellular vesicles modulates neutrophil phenotype and function

    by Harriet E. Allan, Nicola Dark, Paul Vulliamy, Marilena Crescente, Paul C. Armstrong, Plinio Ferreira, Timothy D. Warner

    Platelet activation causes the release of extracellular vesicles, of which a small proportion contain respiratory competent mitochondria. Mitochondria are integral for energy production and in the regulation of apoptotic pathways. However, the existence of extracellular mitochondria highlights a potential new role in intercellular communication. We hypothesised that platelet extracellular vesicles could be taken up by circulatory cells and alter their function. In this work we demonstrate that platelet extracellular vesicles containing mitochondria interact with and are internalised by neutrophils. Flow cytometry revealed that this interaction promotes neutrophil surface receptor changes, indicative of enhanced neutrophil activation, adhesion and migration pathways. The internalisation of platelet mitochondria renders neutrophils unable to subsequently engulf bacteria, demonstrating reduced phagocytic capacity, but enhances the formation of neutrophil extracellular traps, both alone and in the presence of additional stimuli. Our findings show that platelet mitochondria released in extracellular vesicles can alter neutrophil activity and so may be important intercellular communicators and modulators of inflammatory and immune responses.


  • Open Access

    Platelet-derived extracellular vesicles express NADPH oxidase-1 (Nox-1), generate superoxide and modulate platelet function

    by Renato Gaspar, Plinio Ferreira, Joanne L. Mitchell, Giordano Pula, Jonathan M. Gibbins


  • Open Access

    Combination of cyclic nucleotide modulators with P2Y12 receptor antagonists as anti‐platelet therapy

    by Paul C. Armstrong, Plinio M. Ferreira, Melissa V. Chan, Martina H. Lundberg Slingsby, Marilena Crescente, Chih‐Chin Shih, Nicholas S. Kirkby, Adrian J. Hobbs, Timothy D. Warner


  • Platelet reactivity influences clot structure as assessed by fractal analysis of viscoelastic properties

    by Rebecca B. Knowles, Matthew J. Lawrence, Plinio M. Ferreira, Melissa A. Hayman, Lindsay A. D’sIlva, Sophie N. Stanford, Ahmed Sabra, Arthur T. Tucker, Karl M. Hawkins, Phylip R. Williams, et al.

    Despite the interwoven nature of platelet activation and the coagulation system in thrombosis, few studies relate both analysis of protein and cellular parts of coagulation in the same population. In the present study, we use matched ex vivo samples to determine the influences of standard antiplatelet therapies on platelet function and use advanced rheological analyses to assess clot formation. Healthy volunteers were recruited following fully informed consent then treated for 7 days with single antiplatelet therapy of aspirin (75 mg) or prasugrel (10 mg) or with dual antiplatelet therapy (DAPT) using aspirin (75 mg) plus prasugrel (10 mg) or aspirin (75 mg) plus ticagrelor (90 mg). Blood samples were taken at day 0 before treatment and at day 7 following treatment. We found that aspirin plus prasugrel or aspirin plus ticagrelor inhibited platelet responses to multiple agonists and reduced P-selectin expression. Significant platelet inhibition was coupled with a reduction in fractal dimension corresponding to reductions in mean relative mass both for aspirin plus prasugrel (−35 ± 16% change, p = 0.04) and for aspirin plus ticagrelor (−45 ± 14% change, p = 0.04). Aspirin alone had no effect upon measures of clot structure, whereas prasugrel reduced fractal dimension and mean relative mass. These data demonstrate that platelets are important determinants of clot structure as assessed by fractal dimension (df) and that effective platelet inhibition is associated with a weaker, more permeable fibrin network. This indicates a strong association between the therapeutic benefits of antiplatelet therapies and their abilities to reduce thrombus density that may be useful in individual patients to determine the functional relationship between platelet reactivity, eventual clot quality, and clinical outcome. df could represent a novel risk stratification biomarker useful in individualizing antiplatelet therapies.


  • Open Access

    Newly Formed Reticulated Platelets Undermine Pharmacokinetically Short-Lived Antiplatelet Therapies

    by Paul C. Armstrong, Thomas Hoefer, Rebecca B. Knowles, Arthur T. Tucker, Melissa A. Hayman, Plinio M. Ferreira, Melissa V. Chan, Timothy D. Warner

    Objective—: Aspirin together with thienopyridine P2Y 12 inhibitors, commonly clopidogrel, is a cornerstone of antiplatelet therapy. However, many patients receiving this therapy display high on-treatment platelet reactivity, which is a major therapeutic hurdle to the prevention of recurrent thrombotic events. The emergence of uninhibited platelets after thrombopoiesis has been proposed as a contributing factor to high on-treatment platelet reactivity. Here, we investigate the influences of platelet turnover on platelet aggregation in the face of different dual-antiplatelet therapy strategies. Approach and Results—: Traditional light transmission aggregometry, cytometry, advanced flow cytometric imaging, and confocal microscopy were used to follow the interactions of populations of platelets from healthy volunteers and patients with stable cardiovascular disease. Newly formed, reticulated platelets overproportionately contributed to, and clustered at, the core of forming aggregates. This phenomenon was particularly observed in samples from patients treated with aspirin plus a thienopyridine, but was absent in samples taken from patients treated with aspirin plus ticagrelor. Conclusions—: Reticulated platelets are more reactive than older platelets and act as seeds for the formation of platelet aggregates even in the presence of antiplatelet therapy. This is coherent with the emergence of an uninhibited subpopulation of reticulated platelets during treatment with aspirin plus thienopyridine, explained by the short pharmacokinetic half-lives of these drugs. This phenomenon is absent during treatment with ticagrelor, because of its longer half-life and ability to act as a circulating inhibitor. These data highlight the important influences of pharmacokinetics on antiplatelet drug efficacies, especially in diseases associated with increased platelet turnover.


  • Acetylsalicylic Acid Daily vs Acetylsalicylic Acid Every 3 Days in Healthy Volunteers: Effect on Platelet Aggregation, Gastric Mucosa, and Prostaglandin E2Synthesis

    by Plinio Minghin Freitas Ferreira, Thiago Gagliano-Jucá, Tiago Zaminelli, Marinalva Ferreira Sampaio, Rory Willian Blackler, Miriam da Silva Trevisan, Antônio Frederico Novaes Magalhães, Gilberto De Nucci

    Substantial platelet inhibition was observed 3 days after a single administration of acetylsalicylic acid 81 mg to healthy volunteers. Here we investigate prostaglandin E2 (PGE2) antrum concentrations and gastrointestinal symptoms in two treatment groups: one receiving losartan and acetylsalicylic acid every day and the other receiving losartan every day and acetylsalicylic acid every 3 days. Twenty-eight healthy volunteers from both sexes received either 50 mg losartan and acetylsalicylic acid 81 mg daily or 50 mg losartan and acetylsalicylic acid 81 every 3 days with placebo on the other days. Therapy was delivered for 30 days for both groups. Gastric endoscopy was performed before and after treatment period. Biopsies were collected for PGE2 quantification. Platelet function tests were carried out before and during treatment and TXB2 release on platelet rich plasma was measured. The every 3 day low-dose acetylsalicylic acid regimen produced complete inhibition of platelet aggregation compared to the daily treatment. Thromboxane B2 release was substantially abolished for both groups during treatment. There was no significant difference on the endoscopic score of both treatment groups after the 30-day treatment (P = .215). There was over 50% suppression of antrum PGE2 content on volunteers receiving acetylsalicylic acid daily (P = .0016), while for the every 3 day dose regimen there was no significant difference between pre and post-treatment antrum PGE2 dosages (P = .4193). Since PGE2 is involved in gastric healing, we understand that this new approach could be safer and as efficient as the standard daily therapy on a long-term basis.